Senate Joint Resolution 4 is a nonbinding California legislative resolution that asks the President and Congress to rescind recent National Institutes of Health (NIH) actions that limit indirect cost reimbursements and that have led to cancellation of certain grants. The resolution collects the Legislature’s findings — including state-level dollar exposure and examples of canceled research — and formally transmits the Legislature’s objections to federal leaders.
This matters because California is the largest single-state recipient of NIH awards and because the NIH actions at issue target the overhead universities use to run labs, maintain clinical trials, and support compliance. The resolution itself creates no new state regulatory duties, but it signals statewide political pressure, records detailed factual claims (funding totals, affected study areas, and lawsuits), and could influence federal deliberations or motivate state-level mitigation options.
At a Glance
What It Does
SJR 4 formally urges the President and Congress to rescind NIH funding cuts — specifically a February 2025 policy that limits indirect cost reimbursements — and condemns the cancellation of certain research grants. The resolution affirms the Legislature’s commitment to postsecondary institutions and directs the Secretary of the Senate to transmit copies of the resolution to federal and state officials.
Who It Affects
Primary subjects are federally funded biomedical research institutions in California (public and private campuses), principal investigators and research staff whose overhead and grants are reduced, and the state’s biotechnology and life-sciences industry that depends on NIH-supported research and clinical trials.
Why It Matters
Although symbolic, the resolution compiles specific economic and legal claims — including dollar amounts, affected program areas like vaccine hesitancy and DEI research, and active litigation — that make it a concentrated statement of state-level risk. For research administrators and compliance officers, the resolution flags areas of financial exposure and political risk that could drive contingency planning or calls for state remediation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SJR 4 is a formal expression of the California Legislature’s opposition to recent NIH actions that reduce grant support for institutions. The resolution recounts the scale of NIH funding (the bill cites more than $35 billion in 2023 awards nationally and over $5 billion to California institutions), describes how NIH divides grants into direct and indirect costs, and identifies a February 7, 2025 NIH policy that caps indirect cost reimbursements at 15 percent as the proximate cause of harm.
The measure also catalogs operational impacts the Legislature sees as consequential: canceled grants (the text cites examples in vaccine hesitancy and diversity-related research), threats to clinical trials and basic labs, and risks to California’s research workforce. It notes that indirect costs fund essential institutional functions like hazardous-waste disposal, safety compliance, facilities and utilities, and administrative staff — functions that are not easily shifted to project budgets.SJR 4 records that multiple states and institutions have sued to block the NIH action and that a federal judge issued a preliminary injunction placing the cuts on hold while litigation proceeds.
The resolution calls on the federal government to rescind the cap and cancelations and asks the Secretary of the Senate to deliver the resolution to federal leaders and state officials. Legally, the document is hortatory and does not change state law or impose obligations on universities or the federal government; its practical effect is political and informational rather than regulatory.
The Five Things You Need to Know
The resolution specifically objects to a February 7, 2025 NIH policy that limits indirect cost reimbursements on grants to 15 percent, down from an institutional average near 30 percent.
California reports receiving over $5 billion in NIH awards statewide in 2023, with the University of California receiving more than $2 billion and the California State University system receiving roughly $158 million in the last audited year.
SJR 4 lists canceled grants in areas including vaccine hesitancy, LGBTQ+ and gender-identity research, and diversity, equity, and inclusion studies, and warns that mRNA-related research may be targeted next.
The text records that 22 states and multiple research organizations filed lawsuits challenging the NIH cuts and that U.S. District Judge Angel Kelley issued a preliminary injunction temporarily blocking the policy.
The resolution instructs the Secretary of the Senate to transmit copies to federal leaders (President, Vice President, Speaker, Senate Majority Leader, California’s Congressional delegation) and to California’s Governor and Attorney General.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Findings on NIH funding, economic impact, and specific harms
This section collects factual statements the Legislature relies on: national and state NIH award totals, the functional role of indirect costs, examples of research areas affected, and economic multipliers tied to NIH spending. For administrators, these findings are a useful summary of the Legislature’s factual case — they aggregate dollar figures (national and California), list institutional examples (UC and CSU funding levels), and sketch operational consequences like halted clinical trials and canceled DEI and vaccine-hesitancy projects.
Request that federal government rescind NIH cuts and support postsecondary institutions
This operative clause makes the core demand: the Legislature 'calls on' the President and Congress to rescind the NIH limit on indirect costs and to 'cease the attacks' on postsecondary institutions. Mechanically, this is hortatory language; it creates a formal record of displeasure rather than binding obligations. For policy teams, the clause signals California’s readiness to press the federal delegation and to use the resolution in public advocacy and stakeholder communications.
Transmission instructions and recordkeeping
The resolution directs the Secretary of the Senate to send copies to an explicit list of federal and state officials — including the President, Vice President, congressional leaders, California’s congressional delegation, the Governor, and the Attorney General. That text matters practically: it guarantees that the resolution will be included in official correspondence and available to executive-branch recipients and provides a clear chain for advocacy or follow-up inquiries from affected institutions.
This bill is one of many.
Codify tracks hundreds of bills on Science across all five countries.
Explore Science in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- California research universities (public and private) — the resolution publicly documents their exposure and creates an advocacy tool they can use with federal officials and funders to argue for rescission or remediation.
- Principal investigators and research staff working on vaccine hesitancy, LGBTQ+ and DEI topics, and clinical trials — the resolution highlights these program areas and increases public visibility, which can help attract alternative funding or political support.
- Patients and communities relying on clinical trials and biomedical discovery — by opposing cuts to indirect costs, the measure aims (symbolically) to protect studies that translate into diagnostics, therapies, and public-health interventions.
- California’s biotechnology and life sciences employers — the resolution frames NIH funding as an economic engine for jobs and commercialization, reinforcing state-level arguments for support or mitigation measures.
Who Bears the Cost
- Research institutions and university administrations — the NIH cap reduces overhead reimbursements that pay for facilities, compliance, and support staff, forcing institutions to absorb costs or curtail research activity.
- Graduate students, postdocs, and research staff — staff funding, project continuity, and employment tied to grants face increased instability if overhead support is reduced and grants are canceled.
- State budget and policymakers — if federal support shrinks, California faces pressure to consider one-time or ongoing backfill measures, placing new demands on state appropriations or philanthropic solicitation.
- Federal courts and litigants — continued litigation over the NIH policy consumes legal resources and creates uncertainty for grant administration while injunctions are litigated and appealed.
Key Issues
The Core Tension
The central dilemma is a classic public-finance trade-off: impose fiscal controls on federal grant overhead to constrain spending, or preserve negotiated indirect-cost rates to maintain research capacity and long-term public-health and economic returns. SJR 4 chooses the latter rhetorically, but the choice forces a hard question about who ultimately pays for institutional infrastructure — federal taxpayers, state governments, universities, or private sources — and how to balance short-term budget discipline against long-term scientific and economic value.
Two implementation realities limit what SJR 4 accomplishes. First, as a joint resolution, it has no force to change federal agency action; it is a recorded expression of the Legislature’s position.
Its primary utility is political leverage and documentation of state-level harm, not a legal remedy. Second, the resolution rests on contested factual and legal claims that are already the subject of litigation: courts will decide whether the NIH policy is lawful and whether injunctive relief should remain in place, so the resolution’s public pressure operates alongside, but cannot substitute for, judicial outcomes.
There are substantive trade-offs the resolution alludes to but does not resolve. The NIH’s decision to cap indirect costs is framed in some quarters as fiscal restraint and an attempt to standardize reimbursements; the Legislature frames it as an arbitrary cut that undermines infrastructure.
If the federal government rescinds the cap, the immediate research harms would lessen, but the underlying budgetary pressure that prompted the policy would remain. Conversely, if states attempt to backfill lost overhead, they risk creating unfunded long-term obligations and setting a precedent for state-subsidized federal grant programs with attendant fiscal risks.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.